ATC code A04AD13 (WHO) PubChem CID 23725089 UNII 3B03KPM27L | CAS Number 414910-27-3 ChemSpider 25069049 Molar mass 616.26 g/mol | |
 | ||
Synonyms (2R,4S)-4-(4-Acetylpiperazin-1-yl)-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methylpiperidine-1-carboxamide | ||
How to pronounce casopitant
Casopitant (INN, tentative trade names Rezonic (U.S.), Zunrisa (Europe)) is an neurokinin 1 receptor (NK1R) antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV). It is currently under development by GlaxoSmithKline (GSK).
In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.
References
Casopitant Wikipedia(Text) CC BY-SA